A Translational Approach to Gitelman Syndrome

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, they will have the response to 50 mg hydrochlorothiazide on fractional chloride excretion examined.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Oregon Clinical and Translational Research Institute
• Treatments: Hydrochlorothiazide

Criteria

Inclusion Criteria:

1. Institutional Review Board (IRB) approved written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization as per national regulations, must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).

2. Subject is between the ages of 21 and 60.

3. Female subjects of child bearing potential must have a negative urine pregnancy test at the screening visit (Study Visit 1) and must agree to maintain effective birth control during the study.

4. Subjects who are referred to Dr. Ellison for evaluation of normotensive hypokalemia of unknown etiology

Exclusion Criteria:

1. Subject has known allergy to thiazide or sulfonamide medications

2. Subject is pregnant or lactating.

3. Subject has major systemic illnesses that affect potassium regulation through pathology or pharmacologic treatment. This category includes:

• Hypertension

• Requiring regular pharmacological control

• History of blood pressure greater than 140mmHg systolic and 90mmHg diastolic

• Congestive heart failure

• Cirrhosis of the liver

4. Subject has documented kidney disease resulting in anuria, proteinuria or abnormal urinalysis, or requiring dialysis for treatment.